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Negative control of the HGF/c-MET
pathway by TGF-β: a new look at the
regulation of stemness in glioblastoma
Eleanna Papa1, Michael Weller1, Tobias Weiss1, Elisa Ventura1, Isabel Burghardt1 and Emese Szabó1
Abstract
Multiple target inhibition has gained considerable interest in combating drug resistance in glioblastoma, however,
understanding the molecular mechanisms of crosstalk between signaling pathways and predicting responses of
cancer cells to targeted interventions has remained challenging. Despite the signiﬁcant role attributed to transforming
growth factor (TGF)-β family and hepatocyte growth factor (HGF)/c-MET signaling in glioblastoma pathogenesis, their
functional interactions have not been well characterized. Using genetic and pharmacological approaches to stimulate
or antagonize the TGF-β pathway in human glioma-initiating cells (GIC), we observed that TGF-β exerts an inhibitory
effect on c-MET phosphorylation. Inhibition of either mitogen-activated protein kinase (MAPK)/ extracellular signal-
regulated kinase (ERK) or phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/AKT) signaling pathway attenuated
this effect. A comparison of c-MET-driven and c-MET independent GIC models revealed that TGF-β inhibits stemness in
GIC at least in part via its negative regulation of c-MET activity, suggesting that stem cell (SC) maintenance may be
controlled by the balance between these two oncogenic pathways. Importantly, immunohistochemical analyses of
human glioblastoma and ex vivo single-cell gene expression proﬁling of TGF-β and HGF conﬁrm the negative
interaction between both pathways. These novel insights into the crosstalk of two major pathogenic pathways in
glioblastoma may explain some of the disappointing results when targeting either pathway alone in human
glioblastoma patients and inform on potential future designs on targeted pharmacological or genetic intervention.
Introduction
The prognosis of glioblastoma, the most common type
of intrinsic malignant brain tumor, remains poor even
with the current standard of care of the combination of
surgery, radiotherapy, and chemotherapy1,2. Highly inﬁl-
trative growth patterns, cellular and molecular hetero-
geneity, a subpopulation of cells highly resistant to
radiotherapy and chemotherapy, called glioma stem-like
or glioma-initiating cells3–6, and a complex network of
interactions between different tumor cell populations and
the tumor microenvironment7 have been held responsible
for escape from current therapies. Identiﬁcation and
clinical validation of new predictive biomarkers and novel
multi-targeted drug combinations may have the potential
to improve disease control8.
Among the multiple signaling pathways associated with
glioblastoma, the HGF/c-MET and TGF-β pathways have
gained particular attention because of their putative roles
in glioblastoma SC function9–11, in the development of
invasiveness12,13 and resistance to radiotherapy and che-
motherapy14–17 as well as targeted therapies18.
HGF and TGF-β represent members of a large family of
cytokines which are involved in the regulation of
embryonic development and tissue homeostasis8,19. c-MET
is a receptor tyrosine kinase that, after binding its ligand,
HGF, activates a wide range of different cellular signaling
pathways, including those involved in proliferation,
motility, migration and invasion. TGF-β ligands bind and
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activate a heteromeric complex of type I and type II
transmembrane serine/threonine kinase receptors. This
complex is usually formed by ligands, activin receptor-like
kinase (ALK) TGF-β type I receptors (TβR-I) and TGF-β
type II receptors (TβR-II)20. The human genome encodes
seven type I receptors (ALK1-7) and ﬁve type II receptors
(ActR-IIA, ActR-IIB, BMPRII, AMHR-II and TβR-II) that
pair in different combinations as receptor complexes for
various members of the TGF-β family21. Subsequently,
conformational changes in TβR-I allow the phosphoryla-
tion of signaling molecules called receptor-regulated (R)-
SMAD (i.e., SMAD 2,3). The phosphorylated SMAD
together with SMAD4 form transcriptional regulatory
complexes. Translocating into the nucleus, they modulate
the expression of many target genes8. Additional diversity
in TGF-β signaling is achieved via activation of non-
canonical, SMAD-independent pathways, including tumor
necrosis factor (TNF) receptor-associated factor 4
(TRAF4), TRAF6, TGF-β-activated kinase 1 (TAK1; also
known as MAP3K7), p38 mitogen-activated protein kinase
(p38 MAPK), RHO (RAS homolog)-like GTPase signaling
pathways, phosphoinositide 3-kinase (PI3K)—AKT (also
known as protein kinase B), extracellular signal-regulated
kinase (ERK), JUN N-terminal kinase (JNK) or nuclear
factor-κB (NF-κB). Finally, WNT, Hedgehog (HH),
NOTCH, interferon (IFN), TNF, and RAS pathways also
contribute to the complexity of cellular responses to TGF-β
signaling. Gene expression programs controlled by cano-
nical and non-canonical TGF-β signaling pathways may
provide tumor-suppressive or tumor-promoting functions
depending on the tumor type and the stage of tumor
progression22.
Increased c-MET and TGF-β pathway activity may
promote tumor progression in glioblastoma via invasion,
migration, angiogenesis, cell survival, SC maintenance,
and immune evasion13,23–28, however, their potential
interactions may not have been sufﬁciently studied. Here
we report that these two oncogenic pathways may not act
in concert, but act apparently partially antagonistic at
least in human GIC models, potentially accounting for
disappointing results with inhibition of either pathway in
the clinic29–31, but also providing new concepts on how to
modulate these pathways more efﬁciently to improve the
outcome of glioblastoma.
Materials and methods
Reagents
EMD1214063 (c-MET tyrosine kinase inhibitor) was
developed by Merck (Darmstadt, Germany)32. SD-208
(Scios, Inc., Sunnyvale, CA)33 and Galunisertib
(LY2157299 monohydrate) are TβR-I (ALK-5) inhibitors
(Selleckchem, Houston, TX). U0126, inhibitor of MEK1/2
(Cell Signaling Technology, CST Denvers, MA) and
AZD5363, protein kinase B-alpha inhibitor (AstraZeneca,
Cheshire, UK) were used. All drugs were dissolved in
dimethylsulfoxide (DMSO) and diluted in cell culture
medium (ﬁnal solvent concentration ≤0.01%). Recombi-
nant human HGF, TGF-β1 and TGF-β2 were from R&D
Systems (Minneapolis, MN).
Cell culture
ZH-161, ZH-305 and T-269 GIC lines were isolated from
surgically removed glioblastomas34,35. GIC are routinely
authenticated at the Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell Cultures,
Braunschweig, Germany by short tandem repeat analysis,
most recently in 2016. The cells were cultured in neurobasal
medium (NBM) supplemented with 2% B27, 1% glutamine,
epidermal growth factor (EGF, 10 ng/ml), and basic ﬁbro-
blast growth factor (bFGF, 10 ng/ml). The cell lines are
routinely evaluated for in vivo tumorigenicity in nude mice.
Real-time PCR
cDNA generated by reverse transcription from 1 µg total
RNA was used for real-time PCR (RT–PCR). Gene
expression was measured using SYBR Green chemistry
(AppliChem, Darmstadt, Germany) with the RT–PCR
System 7300 (Applied Biosystems, Foster City, CA). All
probes were tested for equal reaction efﬁciencies. The
mean CT values for each sample were used to calculate
relative expression using a variation of the 2^(- delta delta
CT) method36. Speciﬁc target gene expression was nor-
malized to hypoxanthine-guanine phosphoribosyltransfer-
ase 1 (HPRT1) and the relative expression was calculated
using the formula 2^(−delta CT) (ref. 36). The RNA purity
was assessed by the ratio of the absorbance at 260 and 280
nm. RNA quality was veriﬁed by the use of ampliﬁcation
efﬁciency of the reference gene (HPRT1).
Primer sequences are provided in Supplementary
Table S1.
Immunoblot analysis
Whole cell lysates were prepared using radio-
immunoprecipitation assay (RIPA) lysis buffer (pH 7.8)
containing 25 mM Tris-HCl, 120 mM NaCl, 5 mM
EDTA and 0.5% NP-40 supplemented with 100 μg/mL
phenylcmethylsulfonyl ﬂuoride, 200 mM sodium ortho-
vanadate, 0.5 M NaF, protease inhibitor cocktail sets III
and IV and phosphatase inhibitor cocktails 2 and
3 (Sigma-Aldrich). Equal protein concentrations (25 μg)
were loaded and electrophoresis was performed on SDS-
PAGE (8–10%) under reducing conditions. Respective
primary antibodies were purchased from Cell Signaling
Technology, except for anti-phospho-SMAD3 (Abcam,
Cambridge, UK), anti-Ki67 (MIB-1; Dako, Ely, UK),
anti-p21 (C-19; Santa Cruz Biotechnology, Santa Cruz,
CA) and anti-actin (Santa Cruz Biotechnology). The
membranes were exposed to horseradish peroxidase
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(HRP)-conjugated secondary species-speciﬁc antibodies
(Santa Cruz Biotechnology).
Spherogenicity assay
Spherogenicity assays were performed by seeding the cells
at 300 cells/well/100 µl in NB medium using 96-well plates
and allowing them to form spheres for a period of at least
15 days. Spheres containing a minimum of six cells were
scored. Data are expressed as mean± SD normalized to
control.
Flow cytometry
The cells were dissociated with Accutase™ (Chemie
Brunschwig, Basel, Switzerland). For cell cycle analysis 106
cells/condition were ﬁxed and permeabilized with cold
70% ethanol. After two PBS washes, the cells were treated
with RNase A (Gibco, Grand Island, NY) for 30 min at 4 °C
to remove RNA and ensure only DNA is stained with
propidium iodide (PI) (Sigma-Aldrich). For cell death
analysis, 105 cells were re-suspended in Annexin buffer
(10 mM HEPES, 140mM NaCl, 2.5mM CaCl2, pH= 7.4)
and incubated with Annexin-V-FITC (BD Biosciences,
Franklin Lakes, NJ) and PI (Sigma-Aldrich) containing
0.1% Triton X-100 (Sigma-Aldrich) for 15 min at room
temperature. Cells were re-suspended in ﬂow cytometry
buffer (PBS, 0.5% BSA, 0.02% NaN3, 1mM EDTA) and
cell death and cell cycle phases were analyzed by ﬂow
cytometry in a BD FACSVerseTM ﬂow cytometer (Becton
Dickinson AG, Allschwil, Switzerland). Data were analyzed
using FlowJo Software, version 10.0.8 (Ashland, OR).
Enzyme-linked immunosorbent assays (ELISA)
Supernatants of 2× 106 cells were collected after 24 h
and concentrated using an Amicon Ultra centrifugal ﬁlter
(3 K) (Millipore, Temecula, CA). For quantitative detec-
tion of secreted HGF, a HGF ELISA kit (Invitrogen, Basel,
Switzerland) was used.
RNA interference
To silence the expression of SMAD2, SMAD3, SMAD4,
or ALK-5, GIC were transiently transfected by electro-
poration (Neon transfection system, Invitrogen) using
siRNA pools (ON-TARGET plus human SMAD2 siRNA-
SMART pool L-003561-00, ON-TARGET plus human
SMAD3 siRNA-SMART pool L-020067-00-0020, ON-
TARGET plus human SMAD4 siRNA- SMART pool
L-003902-00 and ON-TARGET plus human ALK-5
siRNA- SMART pool L-003929-00 (Dharmacon, Lafay-
ette, CO). Non-targeting siRNA pool was used as a negative
control. Lentiviral pGIPZ vectors encoding c-MET-speciﬁc
(Oligo ID V3LHS_642486) or non-silencing control shRNA
(Oligo ID RHS4346) were purchased from Thermo
Scientiﬁc (Waltham, MA). Glioma cells were transduced
with lentiviral particles produced as described37. Stably
transduced clones were isolated with 4 µg/ml puromycin
and subjected to analyses and assays after 1–5 passage post
selection.
Immunocytochemistry and immunohistochemistry
Glioblastoma patient specimens were obtained and
analyzed in accordance with an Institutional Review
Board-approved project plan (Kantonale Ethikkommission
Zürich, Switzerland, KEK-ZH-Nr./BASCE-Nr. 2016-
00456). Single- or double-antigen labeling of formalin-
ﬁxed and parafﬁn-embedded 4-μm-thick sections by
immunocytochemistry (ICC) or immunohistochemistry
(IHC) included the following steps: deparafﬁnization,
rehydratation, boiling in EDTA buffer (1mM EDTA,
0.05% Tween 20, pH 8.0) for 15min, 1% H2O2 incubation
for 15 min and blocking in SuperBlock solution (ScyTek
Laboratories, Logan, UT) for 30min, followed by primary
antibody application. The following primary antibodies
were used: rabbit anti-phospho-c-METTyr1234/1235 poly-
clonal (R&D Systems), rabbit IgG isotype control (Abcam),
mouse monoclonal anti-TGF-β2 antibody (Abcam) or
mouse IgG1 monoclonal (Abcam). Incubation with these
was followed by HRP-conjugated anti-rabbit IgG second-
ary antibody (Santa Cruz) or the VECTASTAIN ABC-
alkaline phosphatase (AP) detection system (containing
biotinylated anti-mouse IgG) (Vector Labratories, Burlin-
game, CA). For color development Permanent HRP Green
(Zytomed System, Berlin, Germany) and VectorRed
(Vector Labratories) substrate kits were used.
Speciﬁcity veriﬁcation and titration of primary and
secondary antibodies were carried out ﬁrst by ICC
(Fig. S1). 3D-cultured GIC spheres were embedded into
parafﬁn blocks according to a slightly modiﬁed protocol38,
subsequently sectioned and subjected to standard staining
procedures as speciﬁed above.
The evaluation of antigen expression was performed on
tumor regions exhibiting histomorphological features of
glioblastoma including the prominence of glomeruloid
vessels, nuclear atypia, necrosis and high proliferative
activity conﬁrmed by Ki67 staining. The IHC-stained
sections were viewed by a Nikon Eclipse 80i (Nikon
Corporation, Tokyo, Japan) microscope with a Nikon CFI
Plan Apo Lambda 40X (Nikon Corporation) bright ﬁeld
objective, Olympus UC30 (Olympus K.K., Tokyo, Japan)
camera and processed by cellSens Entry 1.12 by Olympus
Corporation (Olympus K.K.) software. To compare the
proportion of each antigen to the other in the same tumor
specimen, the quantiﬁcation of each chromogen was
performed using ImageJ (version 1.32j) software (National
Institutes of Health, http://rsb.info.nih.gov/ij/). TGF-β2
and p-c-MET immunoreactivities were determined by
measuring the integrated density (the sum of the pixel
values) per ﬁeld (tumor region). A cutoff of 5% stained
tumor cells was used to allocate a sample to the TGF-β2
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and p-c-MET high or low groups. The staining procedure,
image acquisition, threshold settings were identical for the
entire set of patient samples. Clinical information on the
cohort of 58 newly diagnosed and 8 recurrent glio-
blastoma patients used in this study has been published39.
Single-cell quantitative RT–PCR of reverse transcribed RNA
Surgically resected glioblastoma tissues were immedi-
ately digested with a papain-based dissociation system
(Worthington, Lakewood, NJ). After digestion, leukocytes
were depleted by using anti-human CD45-conjugated
microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany) and MACS LD columns (Miltenyi Biotec). The
tumor cell population was ﬁltered by excluding CD31-
expressing cells. The single-cell quantitative RT–PCR
(qRT–PCR) was performed at the Federal Institute of
Technology (ETH) Zurich, Department of Biosystems
Science and Engineering (D-BSSE) and Genomics Facility
in Basel by using C1 Single-Cell Autoprep and BioMark
HD instruments (Fludigim, San Francisco, CA). Cq values
were converted to expression levels using the the equa-
tion Log2Ex= Cq LOD (Limit of Detection)—Cq with a LOD
Cq of 25 and data was mean-centered
40.
Statistical analysis
All in vitro experiments reported here were performed
in biological and technical replicates. Quantitative data
were expressed as the mean and SD of triplicate deter-
minations. The statistical analyses were performed by
Student’s t-test and one-way ANOVA with Tukey’s
multiple comparison tests wherever applicable (GraphPad
Software, La Jolla, CA). The Spearman’s rank correlation
coefﬁcient was calculated to analyze the statistical asso-
ciation between the mean of TGF-β2 and p-c-MET levels
(integrated density values) in vivo.
Results
TGF-β suppresses HGF/c-MET pathway activity in
glioblastoma
Patient-derived GIC models referred to as ZH-161, ZH-
305 and T-269 were ﬁrst analyzed for their TGF-β and
HGF/c-MET status to characterize the baseline actvity of
both pathways. All three cell lines expressed TGF-β1 and
TGF-β3 mRNA. TGF-β2 was predominant in ZH-305
whereas ZH-161 was TGF-β2-negative at mRNA and
protein level. (Fig. 1a and Supplementary Fig. S1A, B).
Consistent with the expression of HGF and c-METmRNA,
ZH-161 and ZH-305 exhibited basal levels of phosphory-
lated c-MET (p-c-MET) as demonstrated by immunoblot
and immunocytochemistry (Fig. 1b and Supplementary
Fig. S1A, B). The expression of HGF and c-MET mRNA as
well as the levels of c-MET and p-c-MET protein were
below detection limit in T-269 (Fig. 1b). Therefore, T-269
was used as a negative, whereas ZH-161 and ZH-305 were
used as positive models for c-MET-dependent GIC.
Despite expression of various TGF-β family members, cel-
lular p-SMAD2 levels were low or undetectable (Fig. 1c).
First, we monitored whether TGF-β stimulation modulates
baseline c-MET activity using c-MET-positive GIC models.
Exposure of ZH-161 or ZH-305 cells to recombinant TGF-
β1-induced or TGF-β2-induced activation of TGF-β sig-
naling, as deﬁned by increased p-SMAD2 levels, and
resulted in signiﬁcant reduction of p-c-MET (Fig. 1c and
Supplementary Fig. S2A, B). A minor decrease of the total
c-MET was observed upon TGF-β1 and TGF-β2 stimula-
tion, too. Two different TGF-βRI (ALK-5) inhibitors, SD-
208 and LY2157299, did not affect basal p-c-MET levels,
but prevented the loss of p-c-MET in response to exogen-
ous TGF-β2 (Fig. 1c and Supplementary Fig. S2C). Con-
sistent with the pharmacologic inhibition of ALK-5, its
genetic silencing rescued p-c-MET levels in TGF-β2-treated
cells (Fig. 1c and Supplementary Fig. S2D). The negative
regulation of p-c-MET detected by immunoblot was
demonstrated by ICC (Supplementary Fig. S2E). The
downregulation of p-c-MET was paralleled by a suppres-
sion of HGF mRNA expression and protein release and this
effect was prevented by SD-208 in both cell lines (Fig. 1d, e).
In contrast, c-MET mRNA expression was down-regulated
by exogenous TGF-β2 in ZH-305 only and remained stable
with co-treatment of TGF-β2 and SD-208 in both cell lines
(Supplementary Fig. S2F). Furthermore, exogenous HGF
rescued p-c-MET levels in TGF-β-treated cells (Fig. 1f),
suggesting loss of HGF expression as a mechanism of
negative regulation of the c-MET pathway by TGF-β.
TGF-β activity on HGF/c-MET is regulated by MAPK/ERK
and AKT signaling
To clarify the downstream signaling events resulting in
suppression of c-MET pathway activity, we ﬁrst analyzed
the involvement of SMAD proteins, the central effectors
of TGF-β canonical signaling. We used siRNA oligonu-
cleotides to speciﬁcally silence the expression of SMAD2,
SMAD3 or SMAD4 (Supplementary Fig. S3A–C). Simi-
larly to the ALK-5, SMAD2/3/4 gene silencing did not
alter gene expression of the major effector and down-
stream target of TGF-β, PAI-1 (Supplementary Figs. S2D
and S3D). Exogenous TGF-β2-dependent upregulation of
PAI-1 was lost in SMAD knockdown cells, proving the
efﬁciency of SMAD silencing (Supplementary Fig. S3D).
In contrast to TGF-βRI inhibition, SMAD silencing
did not counteract the TGF-β2-evoked suppression of
p-c-MET. However, SMAD4 siRNA increased p-c-MET
in both GIC lines in the absence of exogenous TGF-β2
(Supplementary Fig. S3B). A similar effect was also
observed with SMAD2 silencing in ZH-305 cells
(Supplementary Fig. S3C).
Since TGF-β2 induces ERK phosphorylation in a
U0126-sensitive manner in glioma cells (Fig. 2a and
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Supplementary Fig. S4A), we next explored a role for ERK
in controlling the HGF/c-MET pathway. U0126 alone
altered neither c-MET phosphorylation nor HGF mRNA
levels but counteracted the inhibitory effect of exogenous
TGF-β2 on p-c-MET and HGF mRNA in ZH-161 and
ZH-305 (Fig. 2a, b). Moreover, U0126 prevented the
downregulation of c-MET mRNA expression by TGF-β2
in ZH-305 (Supplementary Fig. S4B). The involvement of
PI3K/AKT signaling in TGF-β-dependent control of
c-MET pathway was also addressed using the AKT inhi-
bitor, AZD5363. Exposure to TGF-β2 did not modulate
p-AKTThr308/Ser473 and AZD5363 alone did not modify
HGF expression. However, the inhibition of p-AKT by
AZD5363 induced c-MET phosphorylation and the levels
of p-c-MET remained unchanged when the cells were
treated with TGF-β in the presence of AZD5363 (Fig. 2c).
Furthermore, the downregulation of HGF or c-MET
mRNA expression by TGF-β2 was attenuated or pre-
vented by AZD5363 (Fig. 2d and Supplementary
Fig. S4C). The increase of c-MET mRNA by AZD5363 did
not translate into protein level (Fig. 2c and Supplementary
Fig. S4C). The increase of p-AKT (Ser473, Thr308) in
both ZH-161 and ZH-305 (Fig. 2c) reﬂects the mechanism
of drug action41.
Fig. 1 Control of c-MET activity by TGF-β signaling. a, b GIC were assessed for TGF-β 1/2/3 (a) and HGF, c-MET (b) mRNA levels by RT–PCR. Equal
amounts of cellular lysates were assessed also for c-MET and p-c-MET levels by immunoblot (b). c GIC were seeded in complete NB medium in the
presence of SD-208 (1 µM) or TGF-β2 (2 ng/ml) or both, or ALK-5 siRNA (100 nM) with or without TGFβ2 (2 ng/ml) for 24 h. DMSO diluted in NB
medium (1:20’000) served as a control. p-SMAD2, p-c-MET and c-MET protein levels were assessed by immunoblot; 30 µg/lane protein for ZH-161 and
50 µg/lane for ZH-305 were loaded. Actin was used as loading control. Quantiﬁcation of band intensity by ImageJ is shown below the immunoblot
panels. d, e Modulation of HGF mRNA expression (d) and HGF protein release into the supernatant (e) by TGF-β2 stimulation in the absence or
presence of SD-208 was assessed by RT–PCR and by ELISA (*p < 0.05, **p < 0.01, effect of TGF-β2 compared to control, #p < 0.05, ##p < 0.01 effect of
TGF-β2 and SD-208 co-treatment compared to TGF-β2 alone). f The interference of TGF-β2 (2 ng/ml) with HGF (50 ng/ml) stimulation of c-MET
phosphorylation was assessed by immunoblot
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Context-dependent role of HGF/c-MET and TGF-β signaling
in stemness
We next sought to investigate the functional relevance
of the interactions observed between the TGF-β and
c-MET pathways. Given their contribution to the
maintenance of stem-like features of GIC, we ﬁrst eval-
uated how these two pathways alone and their balance
inﬂuence the expression of stem-like markers and self-
renewal capacity. We treated the cells with TGF-β2, or the
ALK-5 inhibitor, SD-208, or the c-MET inhibitor,
EMD1214063. SD-208 alone did not affect OCT-4
(octamer transcription factor), SOX-2 (SRY (sex deter-
mining region Y)-box 2) or NANOG (Nanog homeobox)
mRNA expression. Approximately 2-fold decreases of
these SC marker mRNA expression levels were observed
upon TGF-β2 stimulation in ZH-161 and ZH-305 cells,
except OCT-4 in ZH-305. This reduction was prevented
by SD-208. Similar to TGF-β2, inhibition of c-MET by
EMD1214063 resulted in transcriptional repression of
these genes (Fig. 3). In contrast, none of these markers
were affected by TGF-β2 or EMD1214063 in HGF/c-
MET-negative T-269 cells (Supplementary Fig. S5A).
Accordingly, TGF-β2-treated ZH-161 or ZH-305
showed decreased spherogenesis in a SD-208-sensitive
manner. Similarly, lentivirus-mediated c-MET gene
silencing or c-MET inhibition with EMD1214063 reduced
spherogenicity, but none of that was seen in T-269 cells
(Fig. 4, Supplementary Fig. S4D showing the knockdown
efﬁciency and Supplementary Fig. S5B). The strong effects
on spherogenicity in ZH-161 and ZH-305 may involve
minor cytotoxic and antiproliferative effects of TGF-β2 or
EMD1214063 as demonstrated by changes in viability, cell
cycle progression and increase of the cyclin-dependent
kinase inhibitor p21 under these conditions (Supple-
mentary Fig. S6A–C). To evaluate whether the TGF-β2
effect on stemness was due to its negative control of HGF/
c-MET, we analyzed the spherogenicity upon TGF-β2
exposures in the presence of recombinant HGF. Inter-
estingly, exogenous HGF did not promote spherogenicity
under these culture conditions, however, profound
induction of sphere formation was seen when EGF and
FGF were omitted from the medium in ZH-161 and ZH-
305 except T-269. In addition, the stimulation with HGF
overcame the reduction in sphere formation observed
Fig. 2 (See legend on next column.)
Fig. 2 Analysis of TGF-β downstream signaling components on
c-MET activity. a GIC were treated with U0126 (10 µM) or TGF-β2 (2
ng/ml) alone or combination for 16 h, and assayed for modulation of
c-MET activity by immunoblot. b Modulation of HGF mRNA by the
same treatment (4 h) in both cell lines was evaluated by RT–PCR.
c Quantiﬁcation of c-MET activity and d . HGF mRNA levels upon
AZD5363 (3 µM) or TGF-β2 (2 ng/ml) treatment or their combination
(4 h) was performed by immunoblotting and RT–PCR, respectively.
TGF-β2 was added 1 h later than U0126 and AZD5363. DMSO diluted
in NB medium (1:3’300) was used as a control (*p < 0.05, **p < 0.01,
effect of TGF-β2 compared to control, ωp < 0.05, effect of TGF-β2 and
U0126 or TGF-β2 and AZD5363 co-treatment compared to TGF-β2
alone)
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upon TGF-β2 in ZH-161 and ZH-305 (Supplementary
Fig. S7).
Detection and signiﬁcance of intratumoral TGF-β and HGF/
c-MET heterogeneity in glioblastoma
The ﬁndings of an inhibitory effect on HGF/c-MET by
TGF-β in vitro prompted us to validate an association
between the two pathways in vivo using human glio-
blastoma specimens. The speciﬁcity of the antibodies and
the optimal conditions for IHC were determined using
parafﬁn-embedded positive and negative control cell lines.
TGF-β2 mRNA-expressing ZH-305 cells were immuno-
positive whereas TGF-β2 mRNA-negative ZH-161 cells
were also negative by ICC (Fig. 1a and Supplementary
Fig. S1A). Similar studies were performed to test the anti-
phospho-c-MET antibody in ZH-161 and T-269 cells
which were also characterized for their p-c-MET status by
immunoblot (Fig. 1b and Supplementary Fig. S1B).
We co-stained glioblastoma tissue samples from a
large cohort of 66 different glioblastoma patient for
TGF-β2 (red) and p-c-MET (green) (Fig. 5a–c). p-c-MET
was detected in glioblastoma cells as well as in the vas-
culature. Double staining of TGF-β2 and p-c-MET
allowed the classiﬁcation of the tumor specimens into
four groups (Fig. 5d). In line with our in vitro ﬁndings of
a negative control by TGF-β of c-MET activation, the
two antigens were rarely present simultaneously in the
same tumor specimen (n= 13). Moreover, co-expression
of TGF-β2 and p-c-MET in the same tumor cells was
rarely detected (Fig. 5c, see arrowhead), showing that
these two antigens exhibit almost mutually exclusive
staining patterns among patients and within the tumor
from the same patient. This was reﬂected in a negative
Spearman correlation between TGF-β2 and p-c-MET
levels (r=−0.34, p= 0.005).
Correlations among TGF-β, HGF and stem cell markers in
single-cell qRT–PCR analysis using freshly resected
glioblastoma tissues
Finally, we expanded our study to analyze expression
proﬁles of TGF-β, HGF, and a panel of genes essential for
pluripotency in the CD45-/CD31- presumptive tumor cell
population isolated from freshly resected tumor tissue of
6 glioblastoma patients at diagnosis. Single-cell gene
expression analysis revealed that TGF-β1 gene demon-
strated the highest and TGF-β3 the lowest expression
Fig. 3 Modulation of stem cell marker expression by TGF-β or c-MET modulation. OCT-4, SOX-2 or NANOG gene expression upon exposure to
SD-208 (1 µM), TGF-β2 (2 ng/ml) or both (4 h) were assessed by RT–PCR (*p < 0.05, ***p < 0.001, effect of TGF-β2 relative to control; #p < 0.05, ###p <
0.001 effect of TGF-β2 and SD-208 relative to TGF-β2). The c-MET inhibitor EMD1214063 (200 nM) was included as a reference (ωp < 0.05, ωωp < 0.01)
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level of the three family members. Only TGF-β1 levels
correlated positively with TGF-β target gene, PAI-1
(Fig. 6a). HGF gene expression positively correlated with
several SC markers (Fig. 6b). Importantly, there were
negative correlations between TGF-β1 and HGF expres-
sion as well as TGF-β1 and a panel of SC markers (Fig. 6a).
No signiﬁcant relationship between TGF-β 2/3 and HGF
or SC factors was identiﬁed.
Discussion
Glioblastoma is a universally fatal type of cancer char-
acterized by molecular diversity and intratumoral het-
erogeneity42. Potentially as a consequence of the
heterogeneity of functionally redundant cell signaling
networks and multiple genetic alterations43, glioblastoma
remains largely refractory to current approaches of cancer
therapy targeting speciﬁc signaling pathways44. Given
their role in mediating migration and invasiveness, resis-
tance to irradiation and maintenance of the glioma SC
pool, both HGF/c-MET and TGF-β signaling pathways
have been considered as potential therapeutic targets.
Several approaches evaluated the inhibition of TGF-β
signaling in glioma (www.clinicaltrials.gov) using anti-
bodies, antisense oligonucleotides, ligand traps or TGF-β
receptor kinase inhibitors29,45. Similarly, many clinical
trials explored a therapeutic role for HGF/c-MET inhi-
bition, but none of these approaches have been success-
ful30,31,46. The TGF-β pathway suppresses mammary
Fig. 4 Control of spherogenicity by TGF-β or c-MET pathway. ZH-161 or ZH-305 cells were plated at 300 cells/well in NB medium in the absence
or presence of SD-208 (1 µM) or TGF-β2 (10 ng/ml) or SD-208 combined with TGF-β2 in 96-well plates. c-MET shRNA expressing or EMD1214063 (200
nM)-treated ZH-161 or ZH-305. Sphere formation was assessed at day 21 in triplicates (*p < 0.05, effects of TGF-β2 compared to control, #p < 0.05,
effect of TGF-β2 and SD-208 co-treatment compared to TGF-β2 alone; ωp < 0.05, effect of EMD1214063 compared to control, θp < 0.05, effect of
c-MET shRNA compared to control). Spherogenicity was calculated based on the number of spheres and average size of the spheres as indicated
(upper panels). Representative photomicrographs showing sphere formation in each condition for ZH-161 (middle panels) and ZH-305 (lower
panels). The photomicrographs were taken using a 5X objective
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tumorigenesis by antagonizing HGF/c-MET signaling in
ﬁbroblasts47,48. Moreover, TGF-β negatively regulates c-
MET and HGF mRNA levels in human squamous carci-
noma cells49. In astrocytoma cells, TGF-β family ligands
decrease HGF synthesis and secretion50. However, the
functional interactions between TGF-β family members
and HGF/c-MET signaling in glioblastoma remain
uncharacterized.
Here we have elucidated the complex crosstalk between
the TGF-β- and HGF-dependent signaling pathways in
gliobastoma using three patient-derived GIC models as
well as human glioblastoma specimens. We selected ZH-
161 and ZH-305 models with constitutive c-MET acti-
vation and included a c-MET-negative model, T-269, as a
reference (Fig. 1b). We found that TGF-β stimulation
reduced phospho-c-MET in ZH-161 and ZH-305 cells
(Fig. 1c). This was explained by a reduction of HGF
mRNA expression and protein release (Fig. 1d, e). Exo-
genous HGF rescued c-MET pathway activity in the
presence of TGF-β (Fig. 1f). In addition, repression of p-c-
MET was associated with minor reduction of c-MET at
mRNA and protein levels in ZH-305 cells (Fig. 1c and
Supplementary Fig. S2F).
The effect of TGF-β on HGF/c-MET pathway activation
was prevented upon pharmacological or genetic inhibition of
ALK-5 (Fig. 1c, Supplementary Fig. S2C,D). Silencing of
SMAD2 or SMAD4 gene expression increased basal p-c-
MET levels, indicating a negative regulation of c-MET by
SMAD at basal levels (Supplementary Fig. S3). In contrast
with SMAD2/3/4, only the blockade of the MAPK/ERK
cascade by U0126 and the PI3K/AKT signaling by AZD5363
attenuated the effect of TGF-β on c-MET phosphorylation
as well as HGF gene expression (Fig. 2). TGF-β leads to the
phosphorylation of ERK 1/2 (Supplementary Fig. S4A—2 h
TGF-β—stimulation), thus deﬁning this pathway probably
as the major mediator of the crosstalk between TGF-β and
c-MET.
In response to exogenous TGF-β, there was only minor
or no stimulation of p-AKT (Fig. 2c), indicating a lack of
direct interaction of TGF-β and PI3K/AKT in these GIC
lines. Therefore, AKT acts as an independent mechan-
ism to modulate the effects of TGF-β on c-MET. Inter-
estingly, induction of c-MET phosphorylation was
observed upon the blockade of PI3K/AKT signaling,
conﬁrming a negative control of c-MET activity by AKT
and warranting clinical investigation to determine the
Fig. 5 Simultaneous detection of TGF-β2 and phosphorylated c-MET in glioblastoma. Double immunostaining was performed on formalin-
ﬁxed, parafﬁn-embedded surgical glioblastoma specimens. The quantiﬁcation of each chromogen was performed separately within three randomly
selected different microscopic ﬁelds of each specimen. Blood vessels were excluded from the measurement. a–c Representative images show
hematoxylin and eosin (H&E) staining (upper panels); p-c-MET immunoreactivity in green ((a, c) middle and lower panels) and TGF-β2 in red ((b, c)
middle and lower panels) in tumor regions of three patients. Nuclei are counter-stained with hematoxylin (blue). The scale bars correspond to 50 μm.
d Graphical representation of the percentage of glioblastomas high/low for either TGF-β2 or p-c-MET or both
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signiﬁcance of p-c-MET as an escape mechanism to
AKT inhibitors (Fig. 2).
The PI3K/AKT and ERK signaling cascades are acti-
vated in response to c-MET and are common down-
stream effectors of many receptor tyrosine kinases19,51.
Some evidence supports that PI3K/AKT and ERK act
downstream of TGF-β, too22,52.
The low baseline TGF-β pathway activity in our GIC
models is reﬂected by undetectable phospho-SMAD2/
SMAD3 by immunoblot (Fig. 1c), furthermore by the
unaltered gene expression of the major downstream
effector gene of TGF-β, PAI-1 upon ALK-5 or SMAD2/3/4
gene silencing (Supplementary Figs. S2D and S3D). Thus,
reduced TGF-β shifts the balance in favor of c-MET
receptor activation in these GIC lines. Notably, PAI-1
transcriptional regulation is known to be stimulated by a
variety of cytokines, including EGF53,54 independenly of
TGF-β, which can explain the relative high basal PAI-1
mRNA levels in these cells.
The TGF-β and HGF/c-MET pathways have been
attributed a role in induction of stem marker factors
essential for GIC maintenance9–11,55,56. OCT-4, NANOG
and SOX-2 contribute to the hallmark characteristics of
stem and putative cancer stem cells by activation of target
genes that encode pluripotency and self-renewal
mechanisms57. We observed that exposure to TGF-β
downregulated SC marker gene expression in c-MET-
positive ZH-161 and ZH-305, but not in c-MET-negative
T-269 cells (Fig.3 and Supplementary Fig. S5A). This was
paralleled by an according suppression of spherogenicity
Fig. 6 Correlations among TGF-β, HGF and stem cell markers upon single-cell qRT–PCR analysis using freshly resected glioblastoma
tissues. a, b Pairwise complete correlations of TGF-β1 vs. HGF, OCT-4, SOX-2, SOX-4, MUSASHI, PAI-1 (a, and HGF vs. OCT-4, SOX-2, SOX-4, NANOG,
MUSASHI, and CD133 (b) mean-centered LOG2Ex values for 437 individual glioblastoma cells from 6 patients are shown. Pearson’s correlation
coefﬁcients are depicted after Bonferroni correction for multiple testing. Pearson’s correlation coefﬁcients for pairwise complete observations were
computed using the corrplot R package version 0.77 and Bonferroni correction was applied to adjust for multiple hypothesis testing. Scatterplots of
signiﬁcant correlations were plotted using the ggpubr R package version 0.1.2. Extreme Cq values of “999” were excluded and low quality cells that
did not express the housekeeping genes ARF-1 were discarded. The primer sequences are provided with Supplementary Table S1
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at 21 days and minor changes in viability and cell cycle
progression at 72 h (Fig. 4 and Supplementary Fig. S6).
c-MET inhibition had the same effects as TGF-β stimu-
lation in these assays. Conversely, T-269 did not respond
to any manipulation of the TGF-β or c-MET pathways
(Supplementary Fig. S5B), showing a paradigm of how SC
behavior is differentially regulated in different cellular
contexts. As previously observed11,23,26,58, we induced
sphere formation by stimulation of c-MET positive GIC
models with HGF only in the absence of EGF and FGF
supplementation (Supplementary Fig. S7). In addition,
under these culture conditions, the stimulation with HGF
overcame the reduction in sphere formation observed
upon exposure to TGF-β2 in ZH-161 and ZH-305 (Sup-
plementary Fig. S7). These ﬁndings suggest that TGF-β
may suppress SC characteristics by preventing c-MET
overactivation in subgroups of gliomas (Fig. 7).
Taken together, the observations allowed to predict that
human glioblastomas would tend to up-regulate either of
both pathways, but not both signaling simultaneously.
This assumption was conﬁrmed by a negative correlation
between TGF-β2 and p-c-MET immunoreactivity upon
double immunostaining in a large cohort of glioblastoma
patients (Fig. 5) as well as by a negative correlation
between TGF-β1 and HGF gene expression at single-cell
level in freshly resected glioblastoma tissues (Fig. 6a).
The positive correlation between HGF and SC marker
gene expression detected by single-cell qRT–PCR analysis,
supports the notion that the SC population is enriched in
HGF/c-MET-positive cells (Fig. 6b). Conversely, TGF-β1
mRNA level negatively correlated with the gene expres-
sion of HGF as well as a panel of genes related to stem-
ness. TGF-β1/2/3mRNA levels did not correlate in single-
cell analysis (data not shown). TGF-β1/2/3 mRNA levels
do not allow the prediction of the respective protein levels
as it was previously shown39. In vitro, TGF-β1 and TGF-
β2 proteins were equally effective in controlling HGF/c-
MET signaling and self-renewal (Fig. 1c; Supplementary
Figs. S2A and S5C). Nevertheless, this data set strongly
corroborates the newly identiﬁed suppressive role of
TGF-β in HGF/c-MET-positive stem-like cells as shown
in our preclinical and clinical analyses.
The modulation of c-MET pathway activity by TGF-β
allows to speculate that subsets of patients with glio-
blastoma would have responded to TGF-β inhibitors such
as galunisertib (LY2157299 monohydrate) with an
increase of c-MET activity and potentially MET-mediated
migration and invasion. This might have counteracted any
potential beneﬁt from TGF-β pathway inhibition2.
Accordingly, c-MET negativity could be explored as a
predictive biomarker for future clinical trials exploring
TGF-β inhibition in glioblastoma.
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Fig. 7 Overview of the control of the HGF/c-MET pathway by
TGF-β in glioblastoma. Illustration of the regulatory mechanisms
involved in the control of c-MET activity by TGF-β, which determine
the stem cell phenotype in c-MET-positive human glioma cells
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